For research use only. Not for therapeutic Use.
Pralsetinib hydrochloride (Cat No.: I034991), marketed under the brand name Gavreto, is an orally administered tyrosine kinase inhibitor specifically targeting rearranged during transfection (RET) gene alterations. It is approved for treating metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and RET mutation-positive medullary thyroid cancer (MTC). Pralsetinib binds to RET kinases, inhibiting tumor growth driven by these genetic alterations. Common adverse reactions include elevated liver enzymes, hematologic abnormalities, fatigue, constipation, and hypertension. The U.S. Food and Drug Administration (FDA) granted approval in September 2020.
| Synonyms | BLU-667; BLU 667; BLU667; Pralsetinib HCl; Pralsetinib hydrochloride |
| Molecular Formula | C27H33ClFN9O2 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | (1s,4R)-N-((S)-1-(4-(4-fluoro-1H-pyrazol-1-yl)phenyl)ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)cyclohexane-1-carboxamide hydrochloride |
| InChI | InChI=1S/C27H32FN9O2.ClH/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37;/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36);1H/t18-,19-,27-;/m0./s1 |
| InChIKey | CCYKAXKRSKSMNX-MJFWUJRASA-N |
| SMILES | O=C([C@@]1(OC)CC[C@@H](C2=NC(NC3=NNC(C)=C3)=CC(C)=N2)CC1)N[C@H](C4=CC=C(N5N=CC(F)=C5)N=C4)C.[H]Cl |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
